More than 230,000 women and girls have been diagnosed with HIV in the United States; this year’s theme focuses on prevention.

The U.S. PEPFAR program analyzed PrEP scale-up patterns and found that growth was greater among cisgender heterosexuals.

Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.

In a recent small study, resistance was limited to the emtricitabine component of Truvada and did not seem a major cause for concern.

Under the bill, intentionally transmitting HIV to a sexual partner is reduced from a felony to a misdemeanor. And that’s not all.

From the new coronavirus to “unsafe” sex, Bob Leahy writes about how we all process risk differently and why that’s OK.

Misleading ads about Truvada as PrEP continue to impede HIV prevention.

This is especially the case for people globally who don’t have access to such newer regimens.

Researchers examined increasing use of PrEP, expanding access to opioid use disorder treatment and improving engagement with HIV care.

The International AIDS Conference takes place July 6 to 10 in San Francisco and Oakland.